NASDAQ:IOBT IO Biotech Q3 2025 Earnings Report $0.05 0.00 (0.00%) As of 04/7/2026 ProfileEarnings HistoryForecast IO Biotech EPS ResultsActual EPS-$0.28Consensus EPS -$0.31Beat/MissBeat by +$0.03One Year Ago EPSN/AIO Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIO Biotech Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time8:00AM ETUpcoming EarningsIO Biotech's Q4 2025 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) IO Biotech Earnings HeadlinesIO Biotech: After Considering All Strategic Alternatives, Co. Ceased Operations and Filed aVoluntary Petition for Relief Under Provisions of Chapter 7 of Title 11 of U.S ...March 31, 2026 | marketwatch.comWhy Are Shares Of IO Biotech Plummeting?March 31, 2026 | benzinga.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.May 5 at 1:00 AM | Profits Run (Ad)IO Biotech (IOBT) price target decreased by 33.83% to 1.66February 4, 2026 | msn.comIO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment MeasuresJanuary 30, 2026 | quiverquant.comQIO Biotech Provides Corporate UpdateJanuary 30, 2026 | globenewswire.comSee More IO Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email. Email Address About IO BiotechIO Biotech (NASDAQ:IOBT) ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors. Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access. IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.View IO Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings ARM (5/6/2026)AppLovin (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
